Abstract
Zinc exhibits antidepressant-like activity in preclinical tests (the forced swim test and tail suspension test) and in olfactory bulbectomy and chronic unpredictable stress; two models of depression. Zinc also enhances the treatment of depression in humans. In the present study we evaluated the antidepressant activity of zinc in another model of depression-chronic mild stress (CMS) and the effect of zinc treatment on BDNF protein and the mRNA level. In CMS zinc hydroaspartate (10 mg/kg) exhibited a rapid (after 1 week of treatment) antidepressant-like effect. Chronic treatment with zinc induced a 17-39% increase in the BDNF mRNA and protein level in the hippocampus. These data indicate a rapidly acting antidepressant-like activity of zinc in CMS and the involvement of zinc in the regulation of BDNF.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antidepressive Agents / pharmacology*
-
Antidepressive Agents / therapeutic use
-
Behavior, Animal / drug effects
-
Behavior, Animal / physiology
-
Brain / drug effects*
-
Brain / metabolism
-
Brain / physiopathology
-
Brain-Derived Neurotrophic Factor / drug effects*
-
Brain-Derived Neurotrophic Factor / genetics
-
Brain-Derived Neurotrophic Factor / metabolism
-
Chronic Disease / drug therapy
-
Depressive Disorder / drug therapy*
-
Depressive Disorder / metabolism
-
Depressive Disorder / physiopathology
-
Disease Models, Animal
-
Drug Administration Schedule
-
Gene Expression / drug effects
-
Gene Expression / physiology
-
Male
-
RNA, Messenger / drug effects
-
RNA, Messenger / metabolism
-
Rats
-
Rats, Wistar
-
Stress, Psychological / drug therapy*
-
Stress, Psychological / metabolism
-
Stress, Psychological / physiopathology
-
Time Factors
-
Treatment Outcome
-
Zinc Compounds / pharmacology*
-
Zinc Compounds / therapeutic use
Substances
-
Antidepressive Agents
-
Brain-Derived Neurotrophic Factor
-
RNA, Messenger
-
Zinc Compounds